Safety and Efficacy of Intramuscular Tixagevimab-Cilgavimab in Prevention of COVID-19 in Patients Who Are Immunocompromised

Conclusion Tixagevimab-Cilgavimab exhibited a low incidence of COVID-19 and adverse effects in patients who were immunocompromised.PMID:37718610 | DOI:10.7812/TPP/22.180

Source: The Permanente journal - September 18, 2023 Category: General Medicine Authors: Rebecca Moon Andy Tien Joanie Chung Rebecca Pinnelas Roland Lee Jennifer Hwang Farah Brasfield Amandeep Sahota Source Type: research